Today's Breaking News
- Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
- Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
- Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
Latest R&D and Business News
- Evotec jump-starts biologics with acquisition of Just Biotherapeutics
- Debiopharm Expands its Immuno-Oncology Development Program for Debio 1143, with the First IAP Inhibitor/Nivolumab Combination Trial
- Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
- BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
- CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
- Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer
- Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
- Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis
- Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
- Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
- SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors
- Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma